Monte Rosa Therapeutics (GLUE) Price & Analysis

Compare

337 Followers

GLUE Stock Chart & Stats

$9.35

-$0.20(-2.99%)

At close: Jan 08 4:00 PM EST

$9.35

-$0.20(-2.99%)

Day’s Range― - ―

52-Week Range$3.50 - $12.40

Previous CloseN/A

Volume283.19K

Average Volume (3M)2.18M

Market Cap

$609.56M

Enterprise Value$121.20M

Total Cash (Recent Filing)$290.59M

Total Debt (Recent Filing)$41.13M

Price to Earnings (P/E)28.0

Beta1.73

Next Earnings

Nov 06, 2025

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding61,759,350

10 Day Avg. Volume1,460,444

30 Day Avg. Volume2,176,137

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.20

Enterprise Value/Revenue0.68

Enterprise Value/Gross Profit0.71

Enterprise Value/Ebitda5.72

Forecast

1Y Price Target

$16.00

Price Target Upside71.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Collaboration AgreementMonte Rosa announced a second collaboration agreement with Novartis regarding an exclusive license to an undisclosed discovery target and options to license two programs from the Company's preclinical immunology portfolio.

Financial PositionMonte Rosa will receive an upfront payment of $120M from Novartis under the terms of the agreement.

InnovationThe development of a CNS-penetrant NEK7 degrader could open new treatment applications in epilepsy, showcasing Monte Rosa's innovative pipeline.

Pipeline ValidationThe update on the second collaboration agreement with Novartis provides validation for Monte Rosa's QuEEN platform.

Bears Say

Short InterestShort interest in Monte Rosa is at 30.6% of the float.

Stock Market IndicatorShort interest in Monte Rosa is at 30.6% of the float.

Monte Rosa Therapeutics News

Novartis Stock (NVS) Pops as U.S. Approves Pill to Treat Stubborn Skin Flare-Ups

Swiss pharmaceutical giant Novartis ($NVS) has secured the approval of the U.S. health regulator for its new pill...

22d ago

NVS

PFE

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Investors looking for all of the latest insider trades, regulatory actions, and other stock market news are in...

1M ago

Tesla CEO buys shares, China says Nvidia broke antitrust law: Morning Buzz

The major averages were mixed near noon, with traders focused on President Trump’s comments on U.S.-China trade negotiations...

1M ago

Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis

Swiss giant drug producer Novartis ($NVS) has found a new destination for its recent partnership spree. On Monday,...

1M ago

NVS

ARWR

Monte Rosa Therapeutics Partners with Novartis for Immunology

Monte Rosa Therapeutics ( ($GLUE) ) just unveiled an announcement. On September 13, 2025, Monte Rosa Therapeutics AG...

1M ago

GLUE

Monte Rosa Therapeutics announces collaboration with Novartis

Monte Rosa Therapeutics (GLUE) announced an agreement to collaborate with Novartis (NVS) to develop novel degraders for immune-mediated...

1M ago

NVS

GLUE

Monte Rosa Therapeutics Reports Q2 2025 Earnings

Monte Rosa Therapeutics, Inc. ( ($GLUE) ) has released its Q2 earnings. Here is a breakdown of the...

3M ago

GLUE

Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Growth Potential

LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on GLUE stock, giving a Buy rating today....

3M ago

GLUE

Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M

“With the advancement of our third program into clinical development, we continue to efficiently execute across our portfolio...

3M ago

GLUE

Monte Rosa Therapeutics management to meet with Piper Sandler

Meeting to be held in Boston on July 22 hosted by Piper Sandler. Published first on TheFly –...

3M ago

GLUE

Monte Rosa announces first subjects dosed in Phase 1 study of MRT-8102

Monte Rosa Therapeutics (GLUE) announced that the first subjects have been dosed in a Phase 1 study evaluating...

3M ago

GLUE

Monte Rosa Therapeutics announces FDA clearance of IND application for MRT-8102

Monte Rosa Therapeutics (GLUE) announced U.S. Food and Drug Administration, FDA, clearance of an Investigational New Drug, IND,...

5M ago

GLUE

Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Positive Outlook

LifeSci Capital analyst Oliver McCammon has maintained their bullish stance on GLUE stock, giving a Buy rating today....

6M ago

GLUE

Monte Rosa Therapeutics Reports Strong Q1 2025 Earnings

Monte Rosa Therapeutics, Inc. ( ($GLUE) ) has released its Q1 earnings. Here is a breakdown of the...

6M ago

GLUE

GLUE FAQ

What was Monte Rosa Therapeutics’s price range in the past 12 months?

Monte Rosa Therapeutics lowest stock price was $3.50 and its highest was $12.40 in the past 12 months.

What is Monte Rosa Therapeutics’s market cap?

Monte Rosa Therapeutics’s market cap is $609.56M.

When is Monte Rosa Therapeutics’s upcoming earnings report date?

Monte Rosa Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 14 days.

How were Monte Rosa Therapeutics’s earnings last quarter?

Monte Rosa Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.377 by $0.227.

Is Monte Rosa Therapeutics overvalued?

According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Monte Rosa Therapeutics pay dividends?

Monte Rosa Therapeutics does not currently pay dividends.

What is Monte Rosa Therapeutics’s EPS estimate?

Monte Rosa Therapeutics’s EPS estimate is -0.37.

How many shares outstanding does Monte Rosa Therapeutics have?

Monte Rosa Therapeutics has 61,759,350 shares outstanding.

What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?

Monte Rosa Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.377. Following the earnings report the stock price went down -2.982%.

Which hedge fund is a major shareholder of Monte Rosa Therapeutics?

Currently, no hedge funds are holding shares in GLUE

Monte Rosa Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

9.81%

Trailing 12-Months

Asset Growth

4.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on the discovery and development of novel small molecules that harness the body's natural mechanisms to selectively degrade disease-causing proteins. The company operates within the pharmaceutical and biotechnology sectors, with a primary emphasis on advancing therapies for cancer and other serious diseases through its proprietary drug discovery platform.

Monte Rosa Therapeutics (GLUE) Earnings & Revenues

Historic Earnings Reports

GLUE Stock 12 Month Forecast

Average Price Target

$16.00

▲(71.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","10":"$10","17":"$17","6.5":"$6.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.5,10,13.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.92,5.772307692307693,6.624615384615384,7.476923076923077,8.329230769230769,9.181538461538462,10.033846153846154,10.886153846153846,11.73846153846154,12.590769230769231,13.443076923076923,14.295384615384615,15.147692307692308,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.92,5.772307692307693,6.624615384615384,7.476923076923077,8.329230769230769,9.181538461538462,10.033846153846154,10.886153846153846,11.73846153846154,12.590769230769231,13.443076923076923,14.295384615384615,15.147692307692308,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.92,5.772307692307693,6.624615384615384,7.476923076923077,8.329230769230769,9.181538461538462,10.033846153846154,10.886153846153846,11.73846153846154,12.590769230769231,13.443076923076923,14.295384615384615,15.147692307692308,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.12,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >